Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — H1 2025 Earnings Presentation
21 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2025
Slide 1: 1H2025 Company Update
1H2025 Company Update PT Prodia Widyahusada Tbk | PRDA.JK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Key Updates
Key Updates
Slide 4: 1H2025 Key Highlights
1H2025 Key Highlights Wide network throughout Indonesia with more than 50 years of experience The largest private independent clinical lab chain by size of network and revenue with 40.1%* market share in Indonesia IDR 1.03 Trillion USD 63.3 Million 1973 2012 2016 2022 2024 Jun 2025 Founded in 1st an
Slide 5: Continuous Improvement in a Challenging Market
Continuous Improvement in a Challenging Market Ensure sustainability business with innovation, growth, and optimization Visits Revenue Innovation to deliver Precision Medicine (in Million) (in IDR Trillion) CAGR CAGR 2.3 >2.7 1.5% 5.2% Offers more than 3,000 type Referral Partnership with >2.5 1.7 o
Slide 6: Business Highlights
Business Highlights
Slide 7: The Comprehensive Center of Excellence
The Comprehensive Center of Excellence Delivering personalization and precision in multiple customer segment Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, General Medical offering the most Genomic Testing Preventive
Slide 8: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model Centralized core operations (hub) while efficiently distributing services through multiple outlets (spokes) 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved Hub and spoke model offers scalable platform reducing Centra
Slide 9: Maintain Strong and Long-Term Relationship
Maintain Strong and Long-Term Relationship Generate new tests and ongoing referrals in partnership with medical & scientific community Strong relationships through the work Introduced new tests, such as NIPT ProSafe, CArisk, of more than 500 Marketing and DIArisk, New Born Screening, Autoimmune Live
Slide 10: Be The Next Generation Laboratory
Be The Next Generation Laboratory To deliver precision medicine with comprehensive lab services Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Predictive & Separation Science Diagnostic Laboratory Laboratory Next Generation Laboratory Anatomical Pathology Cancer Molecular La
Slide 11: Business Update
Business Update
Slide 12: Expand Our Presence with Diverse Models
Expand Our Presence with Diverse Models With strategic expansion of outlets, ensuring proximity to our customers 2024 1H2025 Digital Platform 2025 Outlet Development Target Optimization 11 4** 10 4** >5 Hospital Labs Management 354 149* 375 149* includes hospital lab & genomic site Outlets Outlets 1
Slide 13: Deliver Solutions for Customer Needs
Deliver Solutions for Customer Needs Highly personalized approach across multiple channels • Routine, Esoteric, • Prodia for Doctor Genomic Tests • ProdiaLink for External Referrals • Wellness Package Professional Contact Centre • Call Centre 1500-830 • Referral Portal • Disease Screening Package •
Slide 14: Financial Update
Financial Update
Slide 15: Soft Performance in 1H2025 Revenue
Soft Performance in 1H2025 Revenue Market becoming more competitive and tighter budget remain as challenges Revenue (Unaudited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion 1H19-1H25 CAGR +4.3% 2019 2020 2021 2022 • 1H25 performance 2023 2024 2025 mostly driven by 1H24-1H25 Walk-In Cu
Slide 16: 1H2025 Financial Performance
1H2025 Financial Performance Shows soft performance due to higher COGS and OPEX amid soft revenue performance COGS Gross Profit OPEX Net Income in IDR Billion in IDR Billion In IDR Billion In IDR Billion 1H19-1H25 CAGR +4.5% 1H19-1H25 CAGR +4.1% 1H19-1H25 CAGR +5.1% 1H19-1H25 CAGR -2.6% COGS to reve
Slide 17: 1H2025 Financial Summary
1H2025 Financial Summary Financial performance in 1H2025 was softer than previous year (in IDR Bn) 1H2025 1H2024 Change (in IDR Bn) 1H2025 1H2024 Change Revenue 1,027.3 1,032.3 -0.5% Total Asset 2,574.1 2,618.2 -1.7% Gross Profit 598.3 618.9 -3.3% Total Equity 2,314.9 2,330.7 -0.7% EBIT 63.6 127.3 -
Slide 18: Our Professional Team & Shares Information
Our Professional Team & Shares Information
Slide 19: Experienced & Professional Management Team
Experienced & Professional Management Team With more than 20 years experience in delivering growth and innovation of Prodia 52 Years of 52 Years of 41 Years of 50 Years of 33 Years of Experience Experience Experience Experience Experience Gunawan Endang Joseph Fellipus KeriLestari Keri Lestari Andi
Slide 20: Shareholders Composition
Shareholders Composition Public free float is 24.75% of total with market cap of IDR 2.56 Trillion* PT Prodia Utama Bio Majesty Pte. Ltd.** Public*** 57% 15% 28% 30% Distributor for Contract Research Research, therapy and medical equipment Organization banking of stem cell PT Prodia Widyahusada Tbk
Slide 21: For further Information: PT Prodia Widyahusada Tbk
For further Information: PT Prodia Widyahusada Tbk Prodia Tower. Jalan Kramat Raya No. 150 Jakarta 10430, Indonesia Email: investor.relation@prodia.co.id @prodia_lab @prodia_lab @prodia_lab 1500 830
PT Prodia Widyahusada — H1 2025 Earnings Presentation on 6ix